Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

Rhea-AI Summary

Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker and Dr. James Cummings will present at the World Vaccine Congress Europe 2022 in Barcelona on October 13. Dr. Tucker will discuss nasal mucosal responses to a SARS-CoV-2 oral tablet vaccine at 11:30 a.m. CET, while Dr. Cummings will present findings on immune responses to norovirus G1.1 in elderly subjects at 12:00 p.m. CET. Vaxart develops oral recombinant vaccines aimed at various viruses, emphasizing delivery without refrigeration and eliminating needle-stick risks.

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022.

Presentation Information:

Title: Long-lasting nasal mucosal responses in humans to SARS-CoV-2 following oral tablet vaccine administration of non-replicating adenovirus expressing the S and N proteins
Speaker: Dr. Sean Tucker
Date: Thursday, October 13, 2022
Time: 11:30 a.m. CET / 5:30 a.m. ET

Title: Potent immune responses to norovirus G1.1 evaluated in elderly subjects following oral tablet delivery. A phase 1 placebo-controlled study
Speaker: Dr. James Cummings
Date: Thursday, October 13, 2022
Time: 12:00 p.m. CET / 6:00 a.m. ET

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts

Vaxart Media Relations:	Investor Relations:
Mark Herr	Andrew Blazier
Vaxart, Inc.	FINN Partners
mherr@vaxart.com	IR@Vaxart.com
(203) 517-8957	(646) 871-8486

FAQ

What presentations will Vaxart make at the World Vaccine Congress Europe 2022?

Vaxart will present two studies on October 13, 2022: one on nasal responses to a SARS-CoV-2 oral vaccine by Dr. Sean Tucker at 11:30 a.m. CET, and another on immune responses to norovirus in elderly subjects by Dr. James Cummings at 12:00 p.m. CET.

What is the significance of Vaxart's oral tablet vaccines?

Vaxart's oral tablet vaccines are designed to be stored without refrigeration and eliminate the risk of needle-stick injuries, making vaccination more accessible.

What types of vaccines is Vaxart developing?

Vaxart is developing oral vaccines for coronavirus, norovirus, seasonal influenza, respiratory syncytial virus (RSV), and a therapeutic vaccine for human papillomavirus (HPV).

When and where is the World Vaccine Congress Europe 2022 taking place?

The World Vaccine Congress Europe 2022 is scheduled for October 13, 2022, in Barcelona, Spain.

What time do Vaxart's presentations start at the World Vaccine Congress?

Dr. Tucker's presentation starts at 11:30 a.m. CET, and Dr. Cummings' presentation starts at 12:00 p.m. CET on October 13, 2022.